Xcovery

What Xcovery does

Xcovery Holdings, Inc. is a privately held, evidence-based pharmaceutical company founded in 2005 and headquartered in Miami, Florida that develops next-generation, oral small-molecule tyrosine kinase inhibitors (TKIs) for oncology. Its lead asset, ensartinib (brand name ENSACOVE), is a next-generation ALK inhibitor that received FDA approval in December 2024 for first-line treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC); a Phase 3 ELEVATE study published in The New England Journal of Medicine in July 2026 demonstrated an 80% reduction in risk of disease recurrence or death as adjuvant therapy. Its second clinical asset, vorolanib (X-82/CM082), is a multi-kinase angiogenesis inhibitor (VEGFR/PDGFR/CSF1R) being developed for combination use with checkpoint inhibitors and everolimus across NSCLC, SCLC, melanoma, thymic carcinoma, and RCC. The pipeline also includes the investigational MERTK inhibitor MRX-2843 acquired through the 2021 majority acquisition of Meryx Inc.

Xcovery generates revenue through sales of ENSACOVE, jointly developed and co-commercialized with Betta Pharmaceuticals (which holds marketing approvals in China and the United States); U.S. commercialization is executed through an end-to-end partnership with EVERSANA covering market access, commercial teams, and medical affairs. The company maintains a small core team of 11–50 employees, led by CEO Li Mao, CMO/Director Giovanni Selvaggi (formerly Novartis ceritinib lead and BMS thoracic oncology program lead), and Chairman Dr. Lieming Ding (also Chairman/CEO of Betta Pharmaceuticals), with scientific oversight from SAB members Dr. Chris Liang (co-developer of Sutent at SUGEN) and Dr. David Sidransky (former Vice Chairman of ImClone). Customer-facing activity is concentrated through physician engagement at major oncology conferences (WCLC, ASCO, ESMO, ELCC), peer-reviewed publications, and patient-advocacy partnerships with organizations including LUNGevity and the Lung Cancer Alliance.

Name

Xcovery

Legal name

Xcovery Holdings, Inc.

Website

https://xcovery.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Xcovery is a privately held, Miami-based pharmaceutical company developing next-generation oral tyrosine kinase inhibitors for oncology, with FDA-approved ensartinib (ENSACOVE) for ALK-positive NSCLC and a pipeline including vorolanib and the MERTK inhibitor MRX-2843.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industry

Thoracic (Lung) Oncology (HLAKAFAL)

Keywords

• Targeted oncology therapeutics
• Tyrosine kinase inhibitors
• Lung cancer drugs
• ALK inhibitor therapy
• Immuno-oncology combinations

Headquarters

HQ city

West Palm Beach

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Operations, Personnel, Supply Chain

Revenue model

1. Pharmaceutical drug sales - ENSACOVE (ensartinib): Xcovery generates revenue through sales of FDA-approved ENSACOVE (ensartinib) for ALK-positive locally advanced or metastatic NSCLC. Jointly developed with Betta Pharmaceuticals.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Xcovery is a privately held pharmaceutical company that develops next-generation, low-toxicity molecular targeted oral drugs — primarily tyrosine kinase inhibitors — for the treatment of cancer. Its lead commercial asset, ENSACOVE (ensartinib), is an FDA-approved ALK inhibitor for first-line treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer; its pipeline includes vorolanib (a multi-kinase angiogenesis inhibitor for combination immuno-oncology) and MRX-2843 (an investigational MERTK inhibitor).

Differentiator

Problem solved

Functional benefit

Brands

• ENSACOVE (ensartinib): FDA-approved next-generation ALK inhibitor for adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor

Products and services

• ENSACOVE (Ensartinib) ENSACOVE (ensartinib) is an FDA-approved, next-generation ALK inhibitor for the first-line treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). It is a small-molecule tyrosine kinase inhibitor that targets the ALK receptor and demonstrated superior efficacy versus crizotinib in the eXalt3 Phase 3 trial, with activity against ALK alterations including EML4-ALK fusion and resistance point mutations such as T1151M, G1269A, L1196M, G1202R, and V1149M.
• Vorolanib (X-82 / CM082) Vorolanib is a next-generation, small-molecule, multi-kinase inhibitor designed for combination therapies. It provides intermittent inhibition of angiogenesis with once-daily oral dosing, targeting VEGFR, PDGFR, and CSF1R. It has demonstrated promising safety and efficacy in combination with everolimus in renal cell carcinoma and with checkpoint inhibitors (nivolumab, pembrolizumab) across multiple solid tumor types.
• MRX-2843 MRX-2843 is an investigational agent being studied in preclinical models for AML and in dose escalation studies for NSCLC. It is a MERTK inhibitor being developed in collaboration with Meryx Pharmaceuticals (a majority-owned subsidiary of Xcovery).

Quantifiable outcome

• 80% reduction in risk of disease recurrence or death in ALK-positive NSCLC adjuvant setting
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Five partnerships are on record, tiered flagship, core and minor.

• Betta PharmaceuticalsflagshipStrategic or Co-development Partner · 9 July 2026ENSACOVE was jointly developed by Xcovery and Betta Pharmaceuticals. Betta Pharmaceuticals holds marketing approval in China and the United States for ensartinib. The partnership has led to FDA approval in December 2024 and European authorization is under review.
• EVERSANAcoreChannel Partner/ Reseller/ Distributor · 27 April 2026Xcovery partnered with EVERSANA to support the U.S. commercial launch of ENSACOVE (ensartinib). EVERSANA provides comprehensive end-to-end commercialization services including market access, commercial teams, and medical teams to expand patient access across the United States.
• EyePoint PharmaceuticalsminorStrategic or Co-development Partner · 4 May 2022Equinox Sciences expanded vorolanib ophthalmology collaboration with EyePoint Pharmaceuticals for the development of EYP-1901/vorolanib for the treatment of wet AMD.
• Meryx Inc.coreStrategic or Co-development Partner · 7 December 2021Xcovery Holdings acquired a majority and controlling stake in Meryx Inc., a clinical-stage immuno-oncology company based in Chapel Hill, North Carolina developing TKIs in hematologic and solid malignancies including lung cancer. The partnership accelerates development of small molecule oncology drugs for patients worldwide.
• National Cancer Institute (NCI)coreStrategic or Co-development Partner · 31 July 2017Xcovery participates in the NCI Formulary, a public-private partnership between NCI and pharmaceutical companies to expedite the use of investigational agents in clinical trials. Also collaborating with NCI and Children's Oncology Group for the NCI-COG Pediatric MATCH Clinical Trial.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Pfizer: Global pharmaceutical leader with lorlatinib (Lorbrena), a third-generation ALK inhibitor approved for ALK-positive NSCLC — directly competing with Xcovery's ensartinib in the same indication and patient population. Pfizer acquired SUGEN (where Xcovery's co-founder Dr. Chris Liang developed Sutent), making it a relevant comparable on both product and historical talent dimensions.
• Roche: Major oncology incumbent marketing alectinib (Alecensa), a leading second-generation ALK inhibitor approved for first-line ALK-positive NSCLC — a direct head-to-head competitor to ENSACOVE. Roche's global commercial reach and established KOL relationships set the bar Xcovery must clear in the ALK space.
• Novartis: Pharmaceutical major with ceritinib (Zykadia), an ALK inhibitor approved for ALK-positive NSCLC and a direct competitor to ensartinib. Notably, Xcovery Director Giovanni Selvaggi led ceritinib's clinical development at Novartis, creating both a product and talent overlap with Xcovery's leadership.
• Takeda Pharmaceutical: Global pharmaceutical company marketing brigatinib (Alunbrig), a second-generation ALK inhibitor approved for ALK-positive NSCLC, providing another direct competitive comparable in the same indication Xcovery targets with ENSACOVE.

Direct peers

• Betta Pharmaceuticals: Chinese pharmaceutical company that jointly developed ensartinib with Xcovery, holds marketing approvals in China and the U.S., and shares overlapping leadership (Chairman Ding). Comparable as a co-developer in the same molecule and a regional oncology TKI player marketing icotinib (Conmana) in China.
• Turning Point Therapeutics (now Bristol-Myers Squibb): Pre-acquisition developer of repotrectinib (Augtyro), a next-generation ALK/TRK inhibitor approved for ALK-positive NSCLC and ROS1-positive NSCLC — directly overlapping with Xcovery's targeted oncology franchise. Acquired by Bristol-Myers Squibb in 2022 for $4.1B, providing a recent valuation comparable for late-stage TKI developers.
• Exelixis: Oncology-focused biotech marketing cabozantinib (CABOMETYX/Cabometyx), a multi-kinase inhibitor approved for RCC and other indications. Directly comparable to vorolanib's RCC and multi-tumor combination strategy, and a model for how a small-cap TKI franchise can scale commercially.
• Blueprint Medicines: Precision therapy company developing kinase inhibitors including avapritinib (Ayvakit) for genomically-defined cancers. Comparable as a small-to-mid-cap oncology developer with approved kinase-targeted therapies and a similar model of partnership-driven global commercialization.

Emerging players

• Nuvalent: Clinical-stage oncology company developing next-generation kinase inhibitors including zidesamtinib (NVL-520) for ALK-positive NSCLC. Comparable as an emerging TKI-focused competitor in the same ALK therapeutic space where Xcovery is commercializing ENSACOVE.
• Mirati Therapeutics (now Bristol-Myers Squibb): Targeted oncology developer acquired by Bristol-Myers Squibb in 2024 for $4.8B, focused on KRAS and other kinase-driven cancers. Comparable as a small-cap precision oncology developer with FDA-approved TKI-adjacent assets and similar late-stage development profile.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/Xcovery
• Facebookfacebook.com/Xcovery
• LinkedInlinkedin.com/company/xcovery

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xcovery